Glipizide and Metformin Hydrochloride
Glipizide and Metformin Hydrochloride is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Glipizide and Metformin Hydrochloride; Generic name: GLIPIZIDE AND METFORMIN HYDROCHLORIDE; Drug class: Sulfonylurea [EPC].
| Brand name | Glipizide and Metformin Hydrochloride |
|---|---|
| Generic name | GLIPIZIDE AND METFORMIN HYDROCHLORIDE |
| Drug class | Sulfonylurea [EPC] |
| Manufacturer | Teva Pharmaceuticals USA, Inc. |
| Used for | INDICATIONS AND USAGE Glipizide and metformin hydrochloride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| Dosage | DOSAGE AND ADMINISTRATION General Considerations Dosage of glipizide and metformin hydrochloride tablets must be individualized on the basis of both effectiveness and tolerance while not exceeding the maximum recommended daily dose of 20 mg glipizide/2000 mg metformin. Glipizide and metformin hydrochloride tablets should be given with meals and should be initiated at a low dose, with gradual dose escalation as described below, in order to avoid hypoglycemia (largely due to glipizide), reduce GI |
| Warnings | WARNINGS WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (> 5 mmol/Liter), anion gap acidosis (without e |
| Active ingredient(s) | GLIPIZIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03d9ce02-0559-494c-a53d-de9b9a64b606 |